<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00657514</url>
  </required_header>
  <id_info>
    <org_study_id>07-PAD-01</org_study_id>
    <nct_id>NCT00657514</nct_id>
  </id_info>
  <brief_title>Ranolazine Versus Placebo Effects on Exercise Tolerance in Patients With Heart Disease and Peripheral Arterial Disease</brief_title>
  <official_title>Evaluation of Ranolazine on Skeletal Muscle Endpoints During Exercise In Subjects With Chronic Angina and Peripheral Arterial Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Colorado Prevention Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Colorado Prevention Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      After 6 weeks of maximal Ranolazine therapy, tissue hemoglobin desaturation kinetics will&#xD;
      change compared to placebo in patients with chronic angina and peripheral arterial disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Endpoints:&#xD;
&#xD;
      Primary Endpoint:&#xD;
&#xD;
      • The primary endpoint of this study is the change in the kinetics of tissue hemoglobin&#xD;
      oxygen desaturation (expressed as time constants) following the onset of exercise.&#xD;
&#xD;
      Secondary endpoints of this study include percent and absolute change in:&#xD;
&#xD;
        -  Peak oxygen consumption&#xD;
&#xD;
        -  Pulmonary oxygen uptake on-kinetics&#xD;
&#xD;
        -  Steady state level of tissue hemoglobin desaturation during exercise&#xD;
&#xD;
        -  Recovery kinetics of tissue oxygen saturation following exercise&#xD;
&#xD;
      Adverse events will be collected.&#xD;
&#xD;
      Exploratory Endpoints&#xD;
&#xD;
        -  Peak Walking Time (PWT)&#xD;
&#xD;
        -  Claudication Onset Time (COT)&#xD;
&#xD;
        -  Time to Onset of Angina (TOA)&#xD;
&#xD;
      Study Design:&#xD;
&#xD;
      Investigator-initiated, prospective, randomized, double-blind, placebo-controlled study.&#xD;
&#xD;
      Inclusion Criteria:&#xD;
&#xD;
        1. Males age &gt; 40 years.&#xD;
&#xD;
        2. Subjects must have chronic stable angina, meeting the labeled indications for&#xD;
           ranolazine:&#xD;
&#xD;
           • Ranolazine is indicated for the treatment of chronic angina. Ranolazine should be&#xD;
           reserved for subjects who have not achieved an adequate response with other anti-anginal&#xD;
           drugs.&#xD;
&#xD;
        3. Subjects must have a resting ankle brachial index (ABI) of &lt; 0.90 with a post-exercise&#xD;
           decrement of ≥ 10% in at least one leg, OR a resting ABI of ≥0.90 to ≤ 1.00 with a&#xD;
           post-exercise decrement of ≥ 20% in at least one leg&#xD;
&#xD;
        4. The subject has provided written informed consent to participate, understands the&#xD;
           requirements of the study, and agrees to return for the required assessments&#xD;
&#xD;
      Exclusion Criteria:&#xD;
&#xD;
        1. Non-atherosclerotic diseases of the peripheral circulation by clinical history&#xD;
&#xD;
        2. Unable to complete the first stage of the modified, extended Astrand treadmill protocol&#xD;
&#xD;
        3. Clinically significant ECG abnormalities or changes with exercise on the screening ECG&#xD;
&#xD;
        4. Evidence of critical limb ischemia (CLI)&#xD;
&#xD;
        5. Hepatic impairment (Child-Pugh Classes A [mild], B [moderate], or C [severe])&#xD;
&#xD;
        6. End stage renal disease requiring dialysis&#xD;
&#xD;
        7. Hemoglobin &lt; 12 mg/dL.&#xD;
&#xD;
        8. Platelet count &lt; 90,000/mL.&#xD;
&#xD;
        9. Planned surgical/endovascular intervention for coronary artery disease (CAD) or&#xD;
           peripheral arterial disease (PAD) in the next 3 months&#xD;
&#xD;
       10. Maximal exercise is limited by symptoms other than claudication or angina&#xD;
&#xD;
       11. Significant mental illness or drug abuse within 30 days of enrollment that in the&#xD;
           opinion of the Investigator could impact the subject's ability to successfully complete&#xD;
           the trial&#xD;
&#xD;
       12. Known allergy to ranolazine&#xD;
&#xD;
       13. Pre-existing QTc prolongation on a resting electrocardiogram (ECG) at Screening due to&#xD;
           the risk of worsening of this condition with the use of ranolazine&#xD;
&#xD;
       14. Treatment with QT prolonging drugs such as Class IA (e.g. quinidine) and Class III (e.g.&#xD;
           sotalol, dofetilide), antiarrhythmics, amiodarone, and antipsychotics (e.g.&#xD;
           thioridazine, ziprasidone)&#xD;
&#xD;
       15. Treatment with potent or moderately potent CYP3A inhibitors including ketoconazole and&#xD;
           other azole antifungals, diltiazem, verapamil, macrolide antibiotics, cyclosporine,&#xD;
           rifampin or structurally related rifabutin and rifapentin, phenobarbital, phenytoin,&#xD;
           carbamazepine, St. John's Wort, or human immunodeficiency virus (HIV) protease&#xD;
           inhibitors&#xD;
&#xD;
       16. The subject has previously received ranolazine within the 6-months prior to enrollment&#xD;
&#xD;
       17. The subject has received an investigational drug within 90 days prior to enrollment&#xD;
&#xD;
       18. Type 1 or type 2 diabetes mellitus&#xD;
&#xD;
       19. Congestive Heart Failure, ≥ New York Heart Association (NYHA) Class III&#xD;
&#xD;
       20. History of oxygen dependent Chronic Obstructive Pulmonary Disease (COPD)&#xD;
&#xD;
       21. Body Mass Index (BMI) &gt;35&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Insufficient enrollment&#xD;
  </why_stopped>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>skeletal muscle hemoglobin desaturation kinetics</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>peak exercise oxygen consumption</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary oxygen uptake on-kinetics</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Steady state level of tissue hemoglobin desaturation during exercise</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recovery kinetics of tissue oxygen saturation following exercise</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Walking Time (PWT)</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Claudication Onset Time (COT)</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Onset of Angina (TOA)</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Peripheral Arterial Disease</condition>
  <condition>Angina</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug arm - 500mg tablet po bid up to 1000mg (2 500mg tablets) po bid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>P</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo arm - 1 tablet po bid up to 2 tablets po bid if tolerated</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranolazine</intervention_name>
    <description>500mg tablet po bid up to 1000mg (2 500mg tablets) po bid</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Ranexa, extended-release tablets</other_name>
    <other_name>CVT500</other_name>
    <other_name>light orange</other_name>
    <other_name>NDC Code: 67159-112-04</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 tablet po bid up to 2 tablets po bid if tolerated</description>
    <arm_group_label>P</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males age &gt; 40 years.&#xD;
&#xD;
          -  Subjects must have chronic stable angina, meeting the labeled indications for&#xD;
             ranolazine:&#xD;
&#xD;
        Ranolazine is indicated for the treatment of chronic angina. Ranolazine should be reserved&#xD;
        for subjects who have not achieved an adequate response with other anti-anginal drugs.&#xD;
&#xD;
          -  Subjects must have a resting ankle brachial index (ABI) of &lt; 0.90 with a post-exercise&#xD;
             decrement of ≥ 10% in at least one leg, OR a resting ABI of ≥0.90 to ≤ 1.00 with a&#xD;
             post-exercise decrement of ≥ 20% in at least one leg&#xD;
&#xD;
          -  The subject has provided written informed consent to participate, understands the&#xD;
             requirements of the study, and agrees to return for the required assessments&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Non-atherosclerotic diseases of the peripheral circulation by clinical history&#xD;
&#xD;
          -  Unable to complete the first stage of the modified, extended Astrand treadmill&#xD;
             protocol&#xD;
&#xD;
          -  Clinically significant ECG abnormalities or changes with exercise on the screening ECG&#xD;
&#xD;
          -  Evidence of critical limb ischemia (CLI)&#xD;
&#xD;
          -  Hepatic impairment (Child-Pugh Classes A [mild], B [moderate], or C [severe])&#xD;
&#xD;
          -  End stage renal disease requiring dialysis&#xD;
&#xD;
          -  Hemoglobin &lt; 12 mg/dL.&#xD;
&#xD;
          -  Platelet count &lt; 90,000/mL.&#xD;
&#xD;
          -  Planned surgical/endovascular intervention for coronary artery disease (CAD) or&#xD;
             peripheral arterial disease (PAD) in the next 3 months&#xD;
&#xD;
          -  Maximal exercise is limited by symptoms other than claudication or angina&#xD;
&#xD;
          -  Significant mental illness or drug abuse within 30 days of enrollment that in the&#xD;
             opinion of the Investigator could impact the subject's ability to successfully&#xD;
             complete the trial&#xD;
&#xD;
          -  Known allergy to ranolazine&#xD;
&#xD;
          -  Pre-existing QTc prolongation on a resting electrocardiogram (ECG) at Screening due to&#xD;
             the risk of worsening of this condition with the use of ranolazine&#xD;
&#xD;
          -  Treatment with QT prolonging drugs such as Class IA (e.g. quinidine) and Class III&#xD;
             (e.g. sotalol, dofetilide), antiarrhythmics, amiodarone, and antipsychotics (e.g.&#xD;
             thioridazine, ziprasidone)&#xD;
&#xD;
          -  Treatment with potent or moderately potent CYP3A inhibitors including ketoconazole and&#xD;
             other azole antifungals, diltiazem, verapamil, macrolide antibiotics, cyclosporine, or&#xD;
             human immunodeficiency virus (HIV) protease inhibitors&#xD;
&#xD;
          -  The subject has previously received ranolazine within the 6-months prior to enrollment&#xD;
&#xD;
          -  The subject has received an investigational drug within 90 days prior to enrollment&#xD;
&#xD;
          -  Type 1 or type 2 diabetes mellitus&#xD;
&#xD;
          -  Congestive Heart Failure, ≥ New York Heart Association (NYHA) Class III&#xD;
&#xD;
          -  History of oxygen dependent Chronic Obstructive Pulmonary Disease (COPD)&#xD;
&#xD;
          -  Body Mass Index (BMI) &gt;35&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark R Nehler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Univesity of Colorado at Denver</affiliation>
  </overall_official>
  <overall_official>
    <last_name>William R Hiatt, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Colorado Prevention Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Colorado at Denver</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Denver Health and Hospital Authority (DHHA)</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Veteran Affairs Medical Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Bauer TA, Regensteiner JG, Brass EP, Hiatt WR. Oxygen uptake kinetics during exercise are slowed in patients with peripheral arterial disease. J Appl Physiol (1985). 1999 Aug;87(2):809-16.</citation>
    <PMID>10444643</PMID>
  </reference>
  <reference>
    <citation>Barstow TJ, Lamarra N, Whipp BJ. Modulation of muscle and pulmonary O2 uptakes by circulatory dynamics during exercise. J Appl Physiol (1985). 1990 Mar;68(3):979-89.</citation>
    <PMID>2341363</PMID>
  </reference>
  <reference>
    <citation>Bauer TA, Brass EP, Hiatt WR. Impaired muscle oxygen use at onset of exercise in peripheral arterial disease. J Vasc Surg. 2004 Sep;40(3):488-93.</citation>
    <PMID>15337878</PMID>
  </reference>
  <verification_date>August 2014</verification_date>
  <study_first_submitted>April 8, 2008</study_first_submitted>
  <study_first_submitted_qc>April 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 14, 2008</study_first_posted>
  <last_update_submitted>August 13, 2014</last_update_submitted>
  <last_update_submitted_qc>August 13, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 15, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Colorado Prevention Center</investigator_affiliation>
    <investigator_full_name>Mark Nehler, MD</investigator_full_name>
    <investigator_title>Chief, Section of Vascular Surgery and EndoVascular Therapy and Podiatry</investigator_title>
  </responsible_party>
  <keyword>hemoglobin desaturation kinetics</keyword>
  <keyword>peripheral arterial disease</keyword>
  <keyword>chronic angina</keyword>
  <keyword>exercise tolerance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angina Pectoris</mesh_term>
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranolazine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

